GLABF (Gemina Laboratories) Ending Cash Position: $-0.00 Mil (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Ending Cash Position?

Gemina Laboratories GLABF -27.59% Ending Cash Position is $-0.00 Mil as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's Ending Cash Position for the quarter that ended in Oct. 2025 was $-0.00 Mil.

Gemina Laboratories's quarterly Ending Cash Position declined from Apr. 2025 ($0.01 Mil) to Jul. 2025 ($0.00 Mil) and declined from Jul. 2025 ($0.00 Mil) to Oct. 2025 ($-0.00 Mil).

Gemina Laboratories's annual Ending Cash Position declined from Jan. 2023 ($0.06 Mil) to Jan. 2024 ($0.00 Mil) but then stayed the same from Jan. 2024 ($0.00 Mil) to Jan. 2025 ($0.00 Mil).

Gemina Laboratories Ending Cash Position Related Terms

Gemina Laboratories Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Ending Cash Position Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Ending Cash Position
0.00 0.92 0.06 0.00 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.00 0.01 0.00 -0.00

Gemina Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gemina Laboratories's Ending Cash Position for the fiscal year that ended in Jan. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.001+0
=0.00

Gemina Laboratories's Ending Cash Position for the quarter that ended in Oct. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-0.011+0.01
=-0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $-0.00 Mil mean?
Gemina Laboratories (GLABF) has a Ending Cash Position of $-0.00 Mil as of Oct. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Ending Cash Position too high?
Gemina Laboratories' current Ending Cash Position is $-0.00 Mil.
How does Gemina Laboratories' Ending Cash Position compare to VRTX and REGN?
Gemina Laboratories' Ending Cash Position of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current Ending Cash Position is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Ending Cash Position of $-0.00 Mil. The current Ending Cash Position is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Ending Cash Position is $-0.00 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.